Search Results - "Wagner, Samuel C."

Editorial Expression of Concern: Safety of targeting tumor endothelial cell antigens.

Authors: Wagner, Samuel C. Riordan, Neil H. Ichim, Thomas E. et al.

Source: Journal of Translational Medicine. 6/2/2025, Vol. 23 Issue 1, p1-1. 1p.

Safety of targeting tumor endothelial cell antigens.

Authors: Wagner, Samuel C. Riordan, Neil H. Ichim, Thomas E. et al.

Source: Journal of Translational Medicine. 4/12/2016, Vol. 14, p1-12. 12p.

Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?

Authors: Wagner, Samuel C. Ichim, Thomas E. Hong Ma et al.

Source: Journal of Translational Medicine. 10/29/2015, Vol. 13, p1-11. 11p.

Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.

Authors: Wagner, Samuel C. Markosian, Boris Ajili, Naseem et al.

Source: Journal of Translational Medicine. 2014, Vol. 12 Issue 1, p1-19. 19p.

Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax.

Authors: Ichim, Thomas E. Shuang Li Hong Ma et al.

Source: Journal of Translational Medicine. 2015, Vol. 13 Issue 1, p1-9. 9p.

Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.

Authors: Risso V Lafont E Le Gallo M

Source: Cell death & disease [Cell Death Dis] 2022 Mar 17; Vol. 13 (3), pp. 248. Date of Electronic Publication: 2022 Mar 17.

Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE